Amit Garg

Why We Invested In Klivo — Chronic Disease Management Platform

2 min read

Excited to announce our investment alongside Valor Capital in the R$ 45M ($8M) series A of Klivo which provides a chronic disease management platform, starting with diabetes and Brazil. Tau Ventures is an AI-first fund in Silicon Valley investing primarily in seed but we occasionally take later bets when we see immense promise. We are investing in US / Canada but in exceptional cases will consider a deal outside, Klivo being the very first one. The company was founded in 2020 and impressed us with (1) a strong need, (2) building an execution-focused team, and (3) creating a differentiated product…....

This article is free to read

Login to read the full article

OR

By subscribing to our main site, you will also be subscribed to DDIntel - our regular letter showcasing our featured articles and applications.

Amit Garg I have been in Silicon Valley for 20 years -- at Samsung NEXT Ventures, running my own startup (as of May 2019 a series D that has raised $120M and valued at $450M), at Norwest Ventures, and doing product and analytics at Google. My academic training is BS in computer science and MS in biomedical informatics, both from Stanford, and MBA from Harvard. I speak natively 3 languages, live carbon-neutral, am a 70.3 Ironman finisher, and have built a hospital in rural India serving 100,000 people.
«
»

Why We Invested In Handl — Healthcare Price Transparency

Amit Garg
Apr 27, 2024 1 min read

Why Optimism Is Dangerous for Your Financial Well-Being

Olegs Jemeljanovs, PhD, CFA
Apr 27, 2024 2 min read

The Dichotomy With AI for Climate Change

Deepa Ramachandra
Apr 13, 2024 4 min read

Comments are closed.